S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy
Cancers · 05.02.2025 · 17 (3) · 535
DOI: 10.3390/cancers17030535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.02.2025. Verfasst von David Fernández-Ramos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), …. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MICIU/AEI/10.13039/501100011033, NIDDK NIH HHS, Instituto de Salud Carlos III - CIBERehd.
Abstract (Originalsprache)
S-adenosylmethionine (SAMe) is a key methyl donor that plays a critical role in a variety of cellular processes, such as DNA, RNA and protein methylation, essential for maintaining genomic stability, regulating gene expression and maintaining cellular homeostasis. The involvement of SAMe in cancer pathogenesis is multifaceted, as through its multiple cellular functions, it can influence tumor initiation, progression and therapeutic resistance. In addition, the connection of SAMe with polyamine synthesis and oxidative stress management further underscores its importance in cancer biology. Recent studies have highlighted the potential of SAMe as a biomarker for cancer diagnosis and prognosis. Furthermore, the therapeutic implications of SAMe are promising, with evidence suggesting that SAMe supplementation or modulation could improve the efficacy of existing cancer treatments by restoring proper methylation patterns and mitigating oxidative damage and protect against damage induced by chemotherapeutic drugs. Moreover, targeting methionine cycle enzymes to both regulate SAMe availability and SAMe-independent regulatory effects, particularly in methionine-dependent cancers such as colorectal and lung cancer, presents a promising therapeutic approach. Additionally, exploring epitranscriptomic regulations, such as m6A modifications, and their interaction with non-coding RNAs could enhance our understanding of tumor progression and resistance mechanisms. Precision medicine approaches integrating patient subtyping and combination therapies with chemotherapeutics, such as decitabine or doxorubicin, together with SAMe, can enhance chemosensitivity and modulate epigenomics, showing promising results that may improve treatment outcomes. This review comprehensively examines the various roles of SAMe in cancer pathogenesis, its potential as a diagnostic and prognostic marker, and its emerging therapeutic applications. While SAMe modulation holds significant promise, challenges such as bioavailability, patient stratification and context-dependent effects must be addressed before clinical implementation. In addition, better validation of the obtained results into specific cancer animal models would also help to bridge the gap between research and clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Precision Medicine and Metabolism Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
ORCID-Profile: David Fernández-Ramos, Fernando Lopitz-Otsoa, José M Mato
Förderung
- MICIU/AEI/10.13039/501100011033
- NIDDK NIH HHS
- Instituto de Salud Carlos III - CIBERehd
- NIH HHS
- NIH
- Instituto de Salud Carlos III
Zitieren
APA
Fernández-Ramos, D., Lopitz-Otsoa, F., Lu, S. C., & Mato, J. M. (2025). S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy. Cancers, 17(3), 535. https://doi.org/10.3390/cancers17030535
Vancouver
Fernández-Ramos D, Lopitz-Otsoa F, Lu SC, Mato JM. S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy. Cancers. 2025;17(3):535. doi:10.3390/cancers17030535
BibTeX
@article{FernndezRamos2025,
author = {Fernández-Ramos, David and Lopitz-Otsoa, Fernando and Lu, Shelly C and Mato, José M},
title = {S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy},
journal = {Cancers},
year = {2025},
volume = {17},
number = {3},
pages = {535},
doi = {10.3390/cancers17030535}
}
EUVIMED